Vanstapel Arno, Verleden Stijn E, Verbeken Eric K, Braubach Peter, Goos Tinne, De Sadeleer Laurens, Kaes Janne, Vanaudenaerde Bart M, Jonigk Danny, Ackermann Maximilian, Ceulemans Laurens J, Van Raemdonck Dirk E, Neyrinck Arne P, Vos Robin, Verleden Geert M, Weynand Birgit
Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium.
J Clin Med. 2021 Dec 25;11(1):111. doi: 10.3390/jcm11010111.
Bronchiolitis obliterans syndrome (BOS) is considered an airway-centered disease, with bronchiolitis obliterans (BO) as pathologic hallmark. However, the histologic spectrum of pure clinical BOS remains poorly characterized. We provide the first in-depth histopathologic description of well-characterized BOS patients and patients without chronic lung allograft dysfunction (CLAD), defined according to the recent consensus guidelines. Explant lung tissue from 52 clinically-defined BOS and 26 non-CLAD patients (collected 1993-2018) was analyzed for histologic parameters, including but not limited to airway lesions, vasculopathy and fibrosis. In BOS, BO lesions were evident in 38 (73%) patients and varied from concentric sub-epithelial fibrotic BO to inflammatory BO, while 10/14 patients without BO displayed 'vanishing airways', defined by a discordance between arteries and airways. Chronic vascular abnormalities were detected in 22 (42%) patients. Ashcroft fibrosis scores revealed a median of 43% (IQR: 23-69) of normal lung parenchyma per patient; 26% (IQR: 18-37) of minimal alveolar fibrous thickening; and 11% (IQR: 4-18) of moderate alveolar thickening without architectural damage. Patchy areas of definite fibrotic damage to the lung structure (i.e., Ashcroft score ≥5) were present in 28 (54%) patients. Fibrosis was classified as bronchocentric ( = 21/28, 75%), paraseptal ( = 17/28, 61%) and subpleural ( = 15/28, 54%). In non-CLAD patients, BO lesions were absent, chronic vascular abnormalities present in 1 (4%) patient and mean Ashcroft scores were significantly lower compared to BOS ( = 0.0038) with 78% (IQR: 64-88) normally preserved lung parenchyma. BOS explant lungs revealed evidence of various histopathologic findings, including vasculopathy and fibrotic changes, which may contribute to the pathophysiology of BOS.
闭塞性细支气管炎综合征(BOS)被认为是以气道为中心的疾病,以闭塞性细支气管炎(BO)为病理特征。然而,单纯临床BOS的组织学谱仍未得到充分描述。我们根据最近的共识指南,首次对特征明确的BOS患者和无慢性肺移植功能障碍(CLAD)的患者进行了深入的组织病理学描述。对1993年至2018年收集的52例临床诊断为BOS的患者和26例非CLAD患者的移植肺组织进行了组织学参数分析,包括但不限于气道病变、血管病变和纤维化。在BOS患者中,38例(73%)出现BO病变,病变类型从同心性上皮下纤维化性BO到炎症性BO不等,而14例无BO病变的患者中有10例表现为“气道消失”,定义为动脉与气道不一致。22例(42%)患者检测到慢性血管异常。阿什克罗夫特纤维化评分显示,每位患者正常肺实质的中位数为43%(四分位间距:23%-69%);轻度肺泡纤维增厚为26%(四分位间距:18%-37%);中度肺泡增厚且无结构破坏为11%(四分位间距:4%-18%)。28例(54%)患者存在肺结构明确纤维化损伤的斑片状区域(即阿什克罗夫特评分≥5)。纤维化分为支气管中心性(21/28,75%)、间隔旁性(17/28,61%)和胸膜下性(15/28,54%)。在非CLAD患者中,无BO病变,1例(4%)患者存在慢性血管异常,平均阿什克罗夫特评分显著低于BOS患者(P = 0.0038),正常肺实质为78%(四分位间距:64%-88%)。BOS移植肺显示出各种组织病理学发现的证据,包括血管病变和纤维化改变,这可能有助于BOS的病理生理学研究。